Is elimination of HCV in 2030 realistic in Central Europe.


Journal

Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857

Informations de publication

Date de publication:
06 2021
Historique:
received: 22 02 2021
accepted: 22 02 2021
entrez: 22 6 2021
pubmed: 23 6 2021
medline: 29 6 2021
Statut: ppublish

Résumé

According to the recent data presented by Central-European HCV experts, the estimated prevalence of HCV is between 0.2% and 1.7% in certain countries in this region. There are no financial limitations to access to treatment in most countries. Patients in these countries have access to at least one pangenotypic regimen. The most common barriers to the elimination of HCV in Central Europe are a lack of established national screening programmes and limited political commitment to the elimination of HCV. Covid-19 has significantly affected the number of patients who have been diagnosed and treated, thus, delaying the potential elimination of HCV. These data suggest that the elimination of HCV elimination projected by WHO before 2030 will not be possible in the Central Europe.

Identifiants

pubmed: 34155796
doi: 10.1111/liv.14834
doi:

Substances chimiques

Antiviral Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

56-60

Informations de copyright

© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Références

WHO. Global hepatitis report, 2017. Geneva, Switzerland: World Health Organization. http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf
Marshall AD, Cunningham EB, Nielsen S, et al. Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. Lancet Gastroenterol Hepatol. 2018;3(2):125-133.
Cooke GS, Andrieux-Meyer I, Applegate TL, et al. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2019;4(2):135-184.
WHO. Global health sector strategy on viral hepatitis 2016-2021. Geneva, Switzerland: World Health Organization. http://apps.who.int/iris/bitstream/10665/246177/1/WHO-HIV-2016.06-eng.pdf
Razavi H, Gonzalez YS, Pangerl A, et al. Global timing of hepatitis C virus elimination: estimating the year countries will achieve the World Health Organization elimination targets. J Hepatol. 2019;70(1 suppl. 1):E748 (SAT-260).
Flisiak R, Frankova S, Grgurevic I, et al. How close are we to hepatitis C virus elimination in Central Europe? Clin Exp Hepatol. 2020;6(1):1-8.
Blach S, Kondili LA, Aghemo A, et al. Impact of COVID-19 on global hepatitis C elimination efforts [published online ahead of print, 2020 Aug 7]. J Hepatol. 2020;S0168-8278(20)30523-7.

Auteurs

Robert Flisiak (R)

Department of Infectious Diseases and Hepatology, Medical University of Białystok, Białystok, Poland.

Dorota Zarębska-Michaluk (D)

Department of Infectious Diseases, Jan Kochanowski University, Kielce, Poland.

Sona Frankova (S)

Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.

Ivica Grgurevic (I)

Department of Gastroenterology, Hepatology and Clinical Nutrition, University Hospital Dubrava, University of Zagreb School of Medicine, Zagreb, Croatia.

Bela Hunyady (B)

Department of Gastroenterology, First Department of Medicine, Somogy County Kaposi Mór Teaching Hospital, Kaposvár and University of Pécs, Clinical Center, Pécs, Hungary.

Peter Jarcuska (P)

2nd Department of Internal Medicine, Louis Pasteur University Hospital and Pavol Jozej Šafárik University, Faculty of Medicine, Kosice, Slovakia.

Limas Kupčinskas (L)

Institute for Digestive Research and Department of Gastroenterology, Lithuanian University of Health Sciences, Kaunas, Lithuania.

Michael Makara (M)

Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary.

Marieta Simonova (M)

Department of Gastroenterology, HPB Surgery and Transplantology, Military Medical Academy, Sofia, Bulgaria.

Jan Sperl (J)

Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.

Ieva Tolmane (I)

Latvian Center of Infectious Diseases, Riga East University Hospital, Hepatology Department, Faculty of Medicine, University of Latvia, Riga, Latvia.

Adriana Vince (A)

Department for Viral Hepatitis, University Hospital of Infectious Diseases, University of Zagreb School of Medicine, Zagreb, Croatia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH